IRIS
GIULIANI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.466
AS - Asia 14.785
EU - Europa 9.260
SA - Sud America 1.854
AF - Africa 806
Continente sconosciuto - Info sul continente non disponibili 489
OC - Oceania 7
Totale 43.667
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.937
SG - Singapore 5.274
CN - Cina 4.148
VN - Vietnam 2.236
IE - Irlanda 1.616
SE - Svezia 1.524
BR - Brasile 1.440
IT - Italia 1.308
FI - Finlandia 1.133
HK - Hong Kong 1.004
DE - Germania 955
UA - Ucraina 648
BD - Bangladesh 614
FR - Francia 567
ZA - Sudafrica 537
TR - Turchia 524
NL - Olanda 417
CA - Canada 337
GB - Regno Unito 303
IN - India 234
RU - Federazione Russa 182
AR - Argentina 159
AT - Austria 121
MX - Messico 94
JP - Giappone 93
CI - Costa d'Avorio 90
IQ - Iraq 82
ES - Italia 73
KR - Corea 72
RO - Romania 69
BE - Belgio 66
PL - Polonia 66
EC - Ecuador 60
PH - Filippine 60
CZ - Repubblica Ceca 58
PK - Pakistan 56
TH - Thailandia 54
CO - Colombia 50
ID - Indonesia 45
VE - Venezuela 42
UZ - Uzbekistan 39
MA - Marocco 37
LT - Lituania 35
PY - Paraguay 28
CL - Cile 24
TW - Taiwan 24
AE - Emirati Arabi Uniti 23
CR - Costa Rica 23
SA - Arabia Saudita 23
EG - Egitto 22
KE - Kenya 21
IR - Iran 20
UY - Uruguay 20
EU - Europa 18
JO - Giordania 18
MY - Malesia 18
PE - Perù 18
ET - Etiopia 17
TN - Tunisia 17
IL - Israele 16
BG - Bulgaria 15
KZ - Kazakistan 15
JM - Giamaica 14
AL - Albania 13
BO - Bolivia 13
NP - Nepal 12
CH - Svizzera 11
HN - Honduras 10
DO - Repubblica Dominicana 9
DZ - Algeria 9
HU - Ungheria 9
OM - Oman 9
PT - Portogallo 9
SN - Senegal 9
LV - Lettonia 8
QA - Qatar 8
LB - Libano 7
MD - Moldavia 7
NG - Nigeria 7
PA - Panama 7
RS - Serbia 7
SC - Seychelles 7
TT - Trinidad e Tobago 7
AM - Armenia 6
AZ - Azerbaigian 6
GT - Guatemala 6
PS - Palestinian Territory 6
DK - Danimarca 5
GA - Gabon 5
LU - Lussemburgo 5
NI - Nicaragua 5
SY - Repubblica araba siriana 5
AO - Angola 4
AU - Australia 4
BW - Botswana 4
BY - Bielorussia 4
CY - Cipro 4
EE - Estonia 4
GR - Grecia 4
HR - Croazia 4
Totale 43.112
Salva come PNG Salva come JPEG
Città #
Singapore 2.636
Ashburn 1.854
Chandler 1.638
Dublin 1.610
San Jose 1.526
Beijing 1.027
Santa Clara 1.011
Hong Kong 939
Dallas 882
Jacksonville 767
Ho Chi Minh City 667
Council Bluffs 606
Hanoi 516
Boardman 515
Johannesburg 509
Parma 414
Nanjing 410
Izmir 405
Los Angeles 386
Dearborn 383
Ann Arbor 346
New York 342
Princeton 323
Shanghai 322
Lauterbourg 316
San Mateo 233
Munich 214
Wilmington 187
Toronto 174
Shenyang 159
Hefei 156
Kunming 147
Buffalo 142
Marseille 140
São Paulo 138
Nanchang 137
Helsinki 135
Düsseldorf 125
Columbus 108
Jinan 106
Hebei 105
Vienna 99
Moscow 97
Da Nang 95
Abidjan 90
Haiphong 90
Des Moines 88
Tianjin 86
Milan 85
Jiaxing 78
Turku 78
Seattle 76
The Dalles 76
Bremen 74
Tokyo 72
Changsha 66
Brussels 64
Orem 64
Montreal 60
Rome 58
Warsaw 56
Phoenix 55
Houston 54
Woodbridge 54
Brooklyn 53
Kocaeli 52
Guangzhou 50
London 50
Seoul 49
Frankfurt am Main 48
Atlanta 47
Hangzhou 46
Pune 46
Rio de Janeiro 46
Bologna 45
Chicago 44
Hải Dương 41
Nuremberg 41
Amsterdam 40
Poplar 40
Stockholm 40
Focsani 39
Brno 37
Denver 37
Norwalk 37
Biên Hòa 36
Tashkent 35
Zhengzhou 35
Can Tho 34
San Francisco 34
Chennai 33
Boston 30
Piscataway 30
Secaucus 30
Grafing 29
Ankara 27
Naples 27
Dhaka 26
Mexico City 26
Belo Horizonte 25
Totale 25.856
Salva come PNG Salva come JPEG
Nome #
BORTEZOMIB WITH HIGH DOSE MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND IMPROVES THE RESPONSE RATE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA 307
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 232
Are the Myeloma bone microevironment cells tumoral or not? 228
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 224
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 221
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 217
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 214
A simplified sars-cov-2 pseudovirus neutralization assay 213
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 212
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 210
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 209
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 201
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 201
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 198
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 197
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 196
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 196
Novel targets for the treatment of relapsing multiple myeloma 194
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 194
The Proteasome and Myeloma-Associated Bone Disease 193
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 190
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 188
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 188
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 187
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 186
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 186
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 186
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 185
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 185
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 185
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 183
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 182
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 181
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 180
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 178
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 177
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 177
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 176
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 176
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 175
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 174
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 174
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 174
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 172
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 171
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 171
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 170
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 169
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes 167
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 165
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 164
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 163
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 162
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 162
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 162
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 162
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 162
Angiopoietins expression by human myeloma cells 161
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 161
GPNA inhibits the sodium-independent transport system l for neutral amino acids 161
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 160
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 159
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 159
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 159
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 158
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 158
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 157
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 157
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 156
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 155
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 154
Angiogenic switch in multiple myeloma patients 154
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 154
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 154
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 153
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 153
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 153
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 153
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 152
Angiogenic properties of human myeloma cells: role of angiopoietin system 151
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 151
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 151
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 150
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 150
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 150
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 149
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 149
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 149
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 149
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 148
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 148
Angiogenesis and multiple myeloma 148
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 148
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 147
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 147
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 147
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 147
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 146
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 145
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 145
Totale 17.308
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.254
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.557 0 23 26 110 37 57 199 202 77 145 128 553
2022/20236.236 723 644 385 451 531 669 158 398 1.953 74 185 65
2023/20242.278 110 237 55 57 190 623 194 163 54 125 152 318
2024/20257.370 117 402 434 583 797 686 288 319 978 668 632 1.466
2025/202616.969 1.425 1.465 2.034 1.513 2.345 953 1.717 601 2.150 1.322 780 664
2026/20271.283 532 751 0 0 0 0 0 0 0 0 0 0
Totale 43.667